Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100904 · ClinicalTrials.gov registry record
Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry
A clinical trial of Uterine Fibroids, sponsored by University of California, San Francisco.
- Active
- Registry status
- 578
- Enrollment target
- 12
- Study locations
NCT02100904 is a study of Uterine Fibroids that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 578 participants, above the 186-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (211% higher). The trial reports 12 study locations across 6 states.
The verdict
NCT02100904, a study of Uterine Fibroids, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- 578 participants
- Enrollment target
- 12
- Study locations
Study Summary
The ULTRA Registry is a nationwide observational arm of the ULTRA trial. Data from the ULTRA Registry will be used to evaluate the long-term safety and efficacy of laparoscopic RF ablation (Acessa). The ULTRA Registry will recruit women age 21 or older who plan to undergo or have undergone laparoscopic RF ablation (Acessa) or myomectomy within the United States. Participants will be recruited through study materials distributed at clinical offices across the country where gynecologists are performing laparoscopic RF ablation (Acessa). Study participants will consent to participate in a 3 year prospective study conducted by UCSF but the fibroid procedure will be performed by the study participants' own gynecologist. We will evaluate changes in fibroid-related symptoms from pre-treatment values to 6, 12, 18, 24, 30, and 36 months after RFA (Acessa). We will determine long-term efficacy of RFA (Acessa) by evaluating the rate of re-treatment for symptomatic fibroids after the RFA (Acessa) procedure versus myomectomy. Participants will be asked for permission to review their medical records to assess surgical and pregnancy outcomes. UC San Francisco will have oversight of all scientific and administrative aspects of the study. All study data will be stored securely in a HIPAA compliant, secure database monitored by the UC San Francisco Coordinating Center.
Conditions Studied
Interventions
- PROCEDURE Radiofrequency ablation of fibroids
- PROCEDURE Myomectomy of fibroids
Study Locations (12)
Texas
- Tassone Advanced Gynecology - Austin
- UT Southwestern - Dallas
- MacArthur Medical Center - Irving
- Acacia OBGYN - San Antonio
California
- UC Irvine Medical Center - Irvine
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Illinois
- Gynecology Institute of Chicago - Chicago
- Women's Healthcare Associates of IL, SC - Homewood
Delaware
- Dedicated to Women - Dover
Georgia
- Fibroid and Pelvic Wellness Center of Georgia - Alpharetta
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 578 participants |
| Start Date | 2014-05 |
| Est. Completion | 2026-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02100904
The ClinicalTrials.gov registry entry for NCT02100904 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 578 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (211% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uterine Fibroids appearing as the primary indexed condition, and to 2 interventions - of which Radiofrequency ablation of fibroids is the first listed.
NCT02100904 reports 12 study locations spanning 6 distinct geographic areas - top geographies include Texas, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT02100904 about?
NCT02100904 is a clinical study titled "Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry". The ULTRA Registry is a nationwide observational arm of the ULTRA trial. Data from the ULTRA Registry will be used to evaluate the long-term safety and efficacy of laparoscopic RF ablation (Acessa). The ULTRA Registry will recruit women age 21 or older who plan to undergo or have undergone laparosc...
What is the current status of trial NCT02100904?
This trial is currently active not recruiting. The enrollment target is 578 participants. The study started on 2014-05. Estimated completion is 2026-04-01.
What conditions does trial NCT02100904 study?
This clinical trial studies the following conditions: Uterine Fibroids.
What interventions are being tested in trial NCT02100904?
The interventions under investigation include: Radiofrequency ablation of fibroids (PROCEDURE), Myomectomy of fibroids (PROCEDURE).
Who is sponsoring clinical trial NCT02100904?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02100904 being conducted?
This trial has 12 study locations across California, Delaware, Georgia, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Fibroids
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms
RECRUITING · NA
-
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
RECRUITING · Phase 3
-
Effect of Addition of Steroids on Duration of Analgesia
ACTIVE NOT RECRUITING · Early Phase 1
-
Uterine Leiomyoma Treatment With Radiofrequency Ablation
COMPLETED · NA
-
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
COMPLETED · Phase 2
-
Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.